The Supreme Court has delivered a number of important verdicts, with a few more on the way. One such decision important to the health-care industry is on so-called pay-for-delay tactics.

When a drug's patent protection is in dispute, and generic-drug companies routinely challenge the patents of high-profile drugs, a Big Pharma can essentially settle the case by paying a generic-drug company off to not produce a low-cost version of its product, at least for a little while. 

In this video, health-care analyst David Williamson takes a look at how this decision alters pay-for-delay, how it affects Big Pharma and generic-drug makers, and what it all means for investors.

Follow David on Twitter: @MotleyDavid.

David Williamson has no position in any stocks mentioned. Follow David on Twitter: @MotleyDavid.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.